TIVICAY DIN 02414945
Status: Marketed
Holder: VIIV HEALTHCARE ULC
Molecule: DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)
Available to quote
Health Canada record
| Active ingredient(s) | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AJ03 DOLUTEGRAVIR |
| Original market date | 08-Nov-2013 |
| Current status date | 08-Nov-2013 |
| Source | Health Canada DPD |
Establishment licence of the holder
ViiV Healthcare ULC — licence 101800, currently licensed, last inspection rating C (2025-09-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02491753 | DOVATO | VIIV HEALTHCARE ULC | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG; LAMIVUDINE 300 MG | Marketed |
| 02475774 | JULUCA | VIIV HEALTHCARE ULC | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG; RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE) 25 MG | Marketed |
| 02556782 | PMS-DOLUTEGRAVIR | PHARMASCIENCE INC | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG | Marketed |
| 02501457 | SANDOZ DOLUTEGRAVIR | SANDOZ CANADA INCORPORATED | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG | Approved |
| 02511517 | TIVICAY | VIIV HEALTHCARE ULC | Tablet For Suspension | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 5 MG | Marketed |
| 02430932 | TRIUMEQ | VIIV HEALTHCARE ULC | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG; ABACAVIR (ABACAVIR SULFATE) 600 MG; LAMIVUDINE 300 MG | Marketed |
| 02461226 | TIVICAY | VIIV HEALTHCARE ULC | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 25 MG | Cancelled Post Market |
| 02461218 | TIVICAY | VIIV HEALTHCARE ULC | Tablet | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 10 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 14913 | 2013-10-31 | New Drug Submission (NDS) |